 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. NASDAQ: INFI Infinity or the Company, a clinical-stage biotechnology company developing eganelisib IPI-549, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its full year 2020 financial results and provided an update on the Company, including recent progress with eganelisib. Over the past months, we have presented transformative data across multiple indications, 